35results about How to "To achieve the effect of tumor treatment" patented technology

The invention provides two specific T cell receptors targeting G12V or G12C mutation epitopes of a KRAS gene and an anti-tumor application. The two T cell receptors respectively consist of an alpha peptide chain and a beta peptide chain. The invention also provides an antigen binding fragment of the T cell receptors, nucleic acid encoding the antigen binding fragment, a vector containing the nucleic acid, and a host cell containing the vector. The invention further provides a method for preparing a G12V mutation-specific T cell receptor of KRAS or an antigen-binding fragment thereof. The specific T cell receptor and the antigen binding fragment thereof can be used as immune effect activators to stimulate the immune response of the body, thereby generating the action effect of resisting tumors and other diseases.

The invention provides a preparation method of a carrier free nano drug for chemotherapy / light treatment. The drug is prepared by assembling a hydrophobic anticancer drug, a water soluble target, andan amphipathic photosensitizer through a self-assembly technology. The assembled carrier free nano drug is formed through phi-phi accumulation, hydrophobic force, and electrostatic force, is used forchemotherapy and light treatment, and solves the problems that in the prior art, the action mechanism of an artificially synthesized carrier is undefined, and metabolism and most of tumors cannot be inhibited effectively by a single treatment method and still grows slowly.

The invention relates to NIR-II conjugated nano particles and a preparation method and application thereof. The NIR-II conjugated nano particles comprise NIR-II conjugated small molecules and amphiphilic polymers; a structural formula of the NIR-II conjugated small molecules is as follows; and the amphiphilic polymers are self-assembled and encapsulated on the NIR-II conjugated small molecules. The nanoparticles have good biocompatibility, high NIR-II photothermal conversion efficiency, good photoacoustic imaging effect and NIR-II tumor photothermal therapy effect.

The invention discloses a mesoporous silicon nano assembly with tumor cell targeting and a preparation method thereof. The specific steps of the present invention are as follows: (1) first use the surfactant cetyltrimethylammonium bromide as a template, and tetraethyl orthosilicate as a silicon source, under alkaline conditions, at a temperature of 75-85°C The crude product is synthesized, and the surfactant is removed after post-treatment to obtain mesoporous silicon; (2) the mesoporous silicon and the drug are mixed in ethanol to obtain the drug-loaded mesoporous silicon; (3) the drug-loaded mesoporous silicon is treated with phosphate The buffer solution PBS is dispersed, added to the liposome membrane, first hydrated, and then homogenized to obtain the liposome-wrapped mesoporous silicon nanoparticles; (4) react the liposome-wrapped mesoporous silicon nanoparticles with HA Get the target material. The preparation method of the present invention is simple, and the obtained mesoporous silicon nano assembly can enhance the uptake of tumor cells to drugs from two aspects of targeting and preventing drug diffusion, so as to achieve the effect of treating tumors, and has obvious advantages in the treatment of tumors.

The invention discloses water soluble targeting-activated taxol derivatives as well as a preparation method and use thereof. The water soluble targeting-activated taxol derivatives have a following structural formula as shown in the specification, wherein the formula of taxol is also described in the specification, R1 is Ala, Thr, Val or Ile; R2 is Ala, Thr, Val or Asn; and n is equal to 1-150. Compared with taxol, the water soluble targeting-activated taxol derivatives provided by the invention become water soluble type anti-tumor targeting drugs, have specific activation characteristic and immunological enhancement characteristic, and good clinical application prospect, and is greatly improved in the drug action of inhibiting the tumor growth and metastasis, and greatly lowered in toxicity.

The invention belongs to the field of tumor gene therapy, and specifically relates to a recombinant mouse mIL-22BP vector and preparation methods and application of a liposome complex thereof. The invention, in view of the problem that a liposome complex having the murine IL-22BP gene has not been reported so far, provides the recombinant murine IL-22BP vector and the liposome complex thereof. Thevector contains a gene encoding mouse IL-22BP protein and can be used for expressing mouse IL-22BP protein in eukaryotic cells; after vector is combined with a cationic liposome to form the complex,the complex can well play a role of resisting colon cancer tumor tissue growth, has a tumor growth resisting effect, can be used for preparing drugs for diagnosis or treatment of tumors, and providesa new choice for tumor treatment.

The invention provides an application of a long-chain non-coding RNA RP11-224O19.2 inhibitor in preparation of a drug for treating tumors. The invention further provides a drug for treating the tumors, and a kit for liver cancer screening and / or liver cancer prognosis diagnosis. The application shows that the RNA RP11-224O19.2 inhibitor has a significant treatment effect on the tumors. In addition, the expression level of RNA RP11-224O19.2 is detected, and the long-chain non-coding RNA RP11-224O19.2 inhibitor can be applied to auxiliary diagnosis and prognosis judgment of a clinical liver cancer and is good in application prospect.

The invention discloses a selenium-containing photosensitizer as well as a preparation method and application thereof. A novel selenium-containing photosensitizer with an anti-tumor angiogenesis effect is synthesized for a first time. The selenium-containing photosensitizer can be applied to treatment on skin scale cancer and is remarkable in effect, the dosage of the selenium-containing photosensitizer is far lower than that of 5-ALA in the market, in addition is free of antibiotics, free of drug resistance and small in side effect, and is safe and non-toxic and economic and practical; in addition, because of the limited light penetration function and other factors, a tumor treatment effect can be achieved even for tumor tissue without light dynamic response through tumor angiogenesis inhibition.

The invention relates to a probe based on a mesoporous nano carbon sphere doped gold nanoparticle material and a preparation method of the probe. The probe comprises a mesoporous carbon nanosphere, agold nanoparticle growing on the inner orifice wall of the mesoporous carbon nanosphere, an organic fluorescent substance supported in an orifice of the mesoporous carbon nanosphere and a targeting molecule connected to the surface of the mesoporous carbon nanosphere by a chemical bond. Compared with the prior art, the probe can both realize diagnostic monitoring and serve as a therapeutic probe,and has good targeting performance and excellent therapeutic effects based on PTT and PDT. Finally, the synthesized probe successfully ablates tumors (tumors of tumor-bearing mice with MGC-803 cells)and performs fluorescence imaging in vivo and in vitro. In addition, the gold particle located inside the mesoporous carbon nanosphere is not only well protected, but also fully exerts the catalytic effect of a nano-enzyme.

The invention discloses a complex frequency ultrasonic tumor treatment head. The complex frequency ultrasonic tumor treatment head is characterized by comprising an ultrasonic transducer, the ultrasonic transducer comprises a double-end stud, a rear cover board, a front cover board and an insulation sleeve located on the middle section of the double-end stud, and the rear cover board and the front cover board are located on a front thread section and a rear thread section of the double-end stud respectively and compress a first insulation ceramic wafer, a rear piezoelectric ceramic stack, a second insulation ceramic wafer, a mass block, a third insulation ceramic wafer, a front piezoelectric ceramic stack and a fourth insulation ceramic wafer which are sequentially connected to the insulation sleeve in a sleeved mode. A signal generator is utilized for transmitting two signal frequencies, the two piezoelectric ceramic stacks at the two ends of the mass block in the transducer are made to vibrate at different frequencies, the transducer works at a double-frequency mode, the cavitation effect is enhanced through the low frequency generated by difference frequency in the double frequencies, tumor angiogenesis is induced to form thrombus, a tumor nutrition feeding channel is blocked, and the effect of treating a tumor is achieved. The complex frequency ultrasonic tumor treatment head is simple in structure, low in manufacturing cost, and easy and convenient to operate.

The invention discloses a novel Pt(IV) complex with a tumor targeting function. The complex has a structure represented by the formula (I) or the formula (II). The invention discloses a preparation method of the novel Pt(IV) complex. According to the preparation method, an asymmetric ammonia ligand of a Satraplatin carrier group is maintained, a biotin ligand with a targeting function is introduced into one axial end, chloride is introduced into the other end so as to reduce the negative value of the redox potential of the platinum complex, the reducing power is increased at the same time; ora hydroxyl group of the other end is maintained, thus after the Pt(IV) complex enters a human body, the Pt(IV) complex can preferably combine with a reducing agent in the human body, and the Pt(IV) complex is reduced to obtain Pt(II) complex so as to treat the tumors. The provided Pt(IV) complex has antitumor activity on specific tumors, and the toxic effect and side effect are reduced. At the same time, the raw materials are cheap and easily available, the preparation method is simple and is easy to perform, the conditions are mild, the operation is easy, and the preparation method is suitable for large scale production. Z is Cl<->.

The invention relates to the technical field of biomedical technology, and discloses lysosome-targeted pH-sensitive nanoparticle, comprising adriamycin calcium complex Ca-DOX cluster formed by chelating calcium ions Ca<2+> with adriamycin DOX. Fibroin is attached to the surface of the adriamycin calcium complex Ca-DOX cluster. The invention can enable more nanoparticles to be swallowed into the lysine body by cells, the aggregation degree and effective drug loading of nanoparticles in tumor region are improved, and accelerated the decomposition of nanoparticles in lysosomes, so that more Ca<2+> and CO2 are released, adriamycin can be released from the lysosome and enter the cell nucleus to play an anti-tumor role, thus effectively improving the lethality of the tumor, achieving the effectof tumor treatment, and providing a new direction for the clinical treatment of tumor.

The invention provides a cervical cancer therapeutic vaccine based on recombinant attenuated Listeria monocytogenes and a preparation method of the cervical cancer therapeutic vaccine, and relates tothe field of genetic engineering. The attenuated Listeria monocytogenes Lemo-C07 are taken as a background, and a virulence factor LLO protein of the strain carries two key mutant amino acid sites, sothat the virulence of the strain is greatly reduced, but part of the proliferation ability in the cells is still retained. According to the vaccine, on the basis of the attenuated Listeria monocytogenes, a molecular biological technique is utilized to integrate a full-length gene of a specific antigen E7 of the cervical cancer to the downstream part of an LLO gene of the Listeria monocytogenes, thereby constructing and obtaining the recombinant attenuated Listeria monocytogenes containing the tumor specific antigen E7. The vaccine has the capabilities of presenting the specific antigen and activating the anti-tumor cellular immunity of the body, and has the remarkable tumor treatment effect.

The invention provides an anti-tumor ANXA1 derived polypeptide and an application thereof. A series of experiment results prove that the ANXA1 is combined with the EphA2 to protect the EphA2 from being ubiquitinated and degraded by the E3 ubiquitin ligase Cbl, and 20-30 amino acids (namely EYVQTVKSSKG) and 28-30 amino acids (namely SKG) at the N end of the ANXA1 are key regions for combining the ANXA1 and the EphA2. In order to block the combination of ANXA1 and EphA2, 20-30 amino acid polypeptides at the N end of the ANXA1 are synthesized in vitro, the cell-penetrating peptide TAT is used forentering the tumor cells, so that the combination of the ANXA1 and the EphA2 in the tumor cells can be obviously blocked, the combination of Cbl and EphA2 is increased, the ubiquitination degradationof the EphA2 is promoted, the in-vitro and in-vivo growth of the tumor cells is inhibited, and a remarkable anti-tumor effect is achieved. Therefore, the EYVQTVKSSKG polypeptide can be used for preparing antitumor drugs, and has important clinical application value.

The invention provides a T cell epitope specific T cell receptor m2P8D TCR of a human papilloma virus E6 gene, a humanized form h2P8D TCR of the T cell epitope specific T cell receptor m2P8D TCR, andantigen binding fragments of the m2P8D TCR and the h2P8D TCR, and provides nucleic acids encoding the m2P8D TCR, vectors containing the vectors, wherein the two T cell receptors are respectively composed of alpha and beta peptide chains, and also provides nucleic acids encoding the two T cell receptors, a vector containing the nucleic acids, a host cell containing the vector, and anti-tumor applications of the two T cell receptors. The invention further provides a T cell epitope specific T cell receptor m2P8D TCR of the human papilloma virus E6 gene, a humanized form h2P8D TCR of the human papilloma virus E6 gene and preparation methods of the T cell epitope specific T cell receptor m2P8D TCR and the humanized form h2P8D TCR. The two specific T cell receptors and the antigen binding fragments thereof can be used as immune effect activators to stimulate the immune response of the body, thereby generating the action effect of resisting tumors and other diseases.

The invention discloses an application of glipizide in preparing a medicine for treating tumors. The application proves that the glipizide has the effects of inhibiting tumor angiogenesis and tumor proliferation, so that growth and metastasis of tumors can be inhibited, and the effect of treating tumors can be achieved. Furthermore, the glipizide is applied to type 2 diabetes clinically, is safe and reliable, and is a tumor treating medicine with a development prospect.

The invention provides an experimental method of lycium barbarum polysaccharide in inhibition of glioma growth by regulating a blood brain barrier and belongs to the field of traditional Chinese medicine. The experimental method comprises the following steps: taking a male SD rat, feeding for 3-4 weeks with lycium barbarum polysaccharide solution; then constructing a rat glioma model; molding, continuing feeding with the lycium barbarum polysaccharide solution, and detecting, namely firstly detecting survival time, survival rate and median survival time of rats in each group; secondly taking brain tissues of the rats in each group, observing and measuring tumor size; thirdly judging permeability change of the blood brain barrier by carrying out femoral vein Evans blue solution on the rats in each group, taking the same amount of brain tissues and detecting Evans blue content; fourthly observing ultrastructure change of the blood brain barrier by virtue of an electron microscope; fifthly carrying out cardiac apex injection on the rats in each group with paraformaldehyde solution, taking the brain tissues, slicing and then carrying out an immunohistochemical test; and sixthly directly cutting off heads of the rats in each group, taking brains, extracting RNA and proteins and carrying out RT-PCR and Western blotting experiments. The experimental method provided by the invention provides a new treatment approach for treatment of multiple blood brain barrier diseases.

The invention relates to the field of medicines, and in particular relates to polypeptide which can inhibit MYC carcinogenic protein and treat tumor. The sequence of the polypeptide is as shown in SEQ ID NO.1. The polypeptide has the application of tumor treatment. The application includes tumor treatment in multiple administration modes, including subcutaneous or intramuscular injection, intravenous injection or intravenous drip, and the like. The polypeptide has the beneficial effects that in-vitro proliferation activity of multiple tumor cells can be inhibited, MYC protein expression in tumor cells can be promoted, telomerase activity of a tumor cell can be inhibited, growth of tumor inside tumor model naked mice can be inhibited, and the survival rate of tumor-bearing mice can be increased. An effect of treating tumor can be achieved.

The present invention provides human papillomavirus E6 gene T cell epitope-specific T cell receptor murine m2P8D TCR, its humanized form h2P8D TCR, and their antigen-binding fragments. The two T cell receptors are composed of α , β two peptide chains, and also provide nucleic acid encoding them, the vector containing the nucleic acid, the host cell containing the vector and their anti-tumor application; also provide the T cell epitope specific T cell of human papillomavirus E6 gene Cell receptor murine m2P8D TCR, its humanized form h2P8D TCR and methods for their preparation. The two specific T cell receptors and antigen-binding fragments thereof can serve as immune effector activators to stimulate the immune response of the body, thereby producing anti-tumor and other diseases.

The invention relates to a probe based on mesoporous carbon nanospheres doped with gold nanoparticle materials and a preparation method thereof. The probe comprises mesoporous carbon nanospheres, gold nanoparticles grown on the inner channel walls of the mesoporous carbon nanospheres, Organic fluorescent substances loaded in the channels of mesoporous carbon nanospheres and targeting molecules connected on the surface of mesoporous carbon nanospheres through chemical bonds. Compared with the prior art, the present invention can not only realize diagnostic monitoring, but also can be used as a therapeutic probe, and has good targeting and excellent therapeutic effect based on PTT and PDT. Finally, the synthesized probes successfully ablated tumors (tumors of MGC-803 cells in tumor-bearing mice) and were subjected to in vivo and in vitro fluorescence imaging. In addition, the gold particles located inside the mesoporous carbon nanospheres are not only well protected, but also fully play the role of nanozyme catalysis.

The invention discloses a novel Pt(IV) complex with tumor targeting, which has the structure of formula I or formula II. The invention discloses a preparation method of a novel Pt(IV) complex with tumor targeting, which retains the asymmetric ammonia ligand of the Saite platinum carrier group, and introduces a biotin ligand with targeting effect at one axial end , the introduction of chloride at the other end reduces the negative value of the oxidation-reduction potential of the platinum complex and increases the reduction kinetics or retains a hydroxyl group at the other end so that the Pt(IV) complex enters the human body and is conducive to the preferential combination with the reducing agent in the body, reducing to Pt(II) complexes to achieve the effect of treating tumors. It has anti-tumor activity against specific tumors and can reduce its toxic and side effects. At the same time, the raw materials used are cheap and easy to obtain, the method is simple and easy, the conditions are mild, the operation is easy, and the method is suitable for large-scale production. Z is Cl ‑ ,

The invention discloses a complex frequency ultrasonic tumor treatment head. The complex frequency ultrasonic tumor treatment head is characterized by comprising an ultrasonic transducer, the ultrasonic transducer comprises a double-end stud, a rear cover board, a front cover board and an insulation sleeve located on the middle section of the double-end stud, and the rear cover board and the front cover board are located on a front thread section and a rear thread section of the double-end stud respectively and compress a first insulation ceramic wafer, a rear piezoelectric ceramic stack, a second insulation ceramic wafer, a mass block, a third insulation ceramic wafer, a front piezoelectric ceramic stack and a fourth insulation ceramic wafer which are sequentially connected to the insulation sleeve in a sleeved mode. A signal generator is utilized for transmitting two signal frequencies, the two piezoelectric ceramic stacks at the two ends of the mass block in the transducer are made to vibrate at different frequencies, the transducer works at a double-frequency mode, the cavitation effect is enhanced through the low frequency generated by difference frequency in the double frequencies, tumor angiogenesis is induced to form thrombus, a tumor nutrition feeding channel is blocked, and the effect of treating a tumor is achieved. The complex frequency ultrasonic tumor treatment head is simple in structure, low in manufacturing cost, and easy and convenient to operate.

The present invention belongs to the preparation process of transgenic tumor cell for treating malignant tumor, and is especially the preparation process of tumor cell containing interleukin-23 transgene. The tumor treating method of the present invention is superior to available tumor treating methods. Interleukin-23 gene is introduced via carrier into tumor cell to produce interleukin-23 withpowerful tumor resisting effect to treat malignant tumor. It functions in the initial immune response stage and activate dendritic cell to induce natural killing of cell. Interleukin-23 can also induce the proliferation and activation of memory T cell, secret IFN-gamma, regulate immunological function, inhibit the vascularization in tumor part and thus reach the effect of curing malignant tumor.

The invention relates to the technical field of biomedical technology, and discloses lysosome-targeted pH-sensitive nanoparticle, comprising adriamycin calcium complex Ca-DOX cluster formed by chelating calcium ions Ca<2+> with adriamycin DOX. Fibroin is attached to the surface of the adriamycin calcium complex Ca-DOX cluster. The invention can enable more nanoparticles to be swallowed into the lysine body by cells, the aggregation degree and effective drug loading of nanoparticles in tumor region are improved, and accelerated the decomposition of nanoparticles in lysosomes, so that more Ca<2+> and CO2 are released, adriamycin can be released from the lysosome and enter the cell nucleus to play an anti-tumor role, thus effectively improving the lethality of the tumor, achieving the effectof tumor treatment, and providing a new direction for the clinical treatment of tumor.

The invention provides an anti-tumor ANXA1 derived polypeptide and its application. A series of experimental results confirmed that ANXA1 protects EphA2 from being ubiquitinated and degraded by E3 ubiquitin ligase Cbl by binding to EphA2. ) is the key region for the combination of ANXA1 and EphA2. In order to block the combination of ANXA1 and EphA2, ANXA1 N-terminal 20‑30 amino acid polypeptides were synthesized in vitro, and entered into tumor cells with the help of the membrane-penetrating peptide TAT, which could significantly block the combination of ANXA1 and EphA2 in tumor cells, increase the combination of Cbl and EphA2, and promote The ubiquitination and degradation of EphA2 inhibits the growth of tumor cells in vitro and in vivo, and has a significant antitumor effect. Therefore, the EYVQTVKSSKG polypeptide can be used to prepare antitumor drugs and has important clinical application value.

The invention discloses an application of a CAR-T cell targeting AXL, a third generation of CAR-T cell targeting AXL is prepared by using scFv protein targeting AXL, and the CAR-T cell is applied to tumor treatment, so that the problem that a tumor specific target is difficult to find when CAR-T is used for treating solid tumors is solved, target missing is effectively avoided, the probability of side effects is reduced, and the solid tumor treatment effect is improved. Based on high expression of the AXL in lung cancer, the AXL has a specific killing effect on lung cancer tissues with positive expression of the AXL, so that the treatment on the lung cancer is realized; especially, the cell acts on lung cancer cells which are resistant to EGFR-TKI due to up-regulation of AXL, and can significantly improve the treatment effect of lung cancer and overcome the poor treatment effect caused by drug resistance in cooperation with EGFR-TKI drugs in treatment of lung cancer.

The present invention belongs to the preparation process of transgenic tumor cell for treating malignant tumor, and is especially the preparation process of tumor cell containing interleukin-23 transgene. The tumor treating method of the present invention is superior to available tumor treating methods. Interleukin-23 gene is introduced via carrier into tumor cell to produce interleukin-23 with powerful tumor resisting effect to treat malignant tumor. It functions in the initial immune response stage and activate dendritic cell to induce natural killing of cell. Interleukin-23 can also induce the proliferation and activation of memory T cell, secret IFN-gamma, regulate immunological function, inhibit the vascularization in tumor part and thus reach the effect of curing malignant tumor.

The invention discloses a target spot for treating tumors, application of the target spot and a tumor treatment preparation. A series of studies find that PRMT5 and CD38 in nasopharynx cancer, cervical cancer and lung cancer cells interact with each other, and PRMT5 enables CD38 protein to generate arginine methylation, so that the self enzyme activity of CD38 is influenced. Particularly, the 58th amino acid of the CD38 protein is subjected to arginine methylation. In-vivo and in-vitro experiments prove that the 58th arginine of the CD38 protein is changed into a glycine mutant which enters tumor cells, so that PRMT5 cannot enable the 58th arginine of the CD38 protein to be methylated and inhibit the self enzyme activity of the CD38, and further the proliferation and in-vivo tumorigenicity of the tumor cells are promoted by influencing an NAD-SIRT1-p53 axis, so that the effect of treating tumors is achieved. The anti-tumor CD38 is obvious in fixed-point target effect and free of obvious toxic and side effects.

The invention provides the use of the long-chain non-coding RNA RP11‑224O19.2 inhibitor in the preparation of drugs for treating tumors. The invention also provides a drug for treating tumors and a liver cancer screening and / or liver cancer prognosis diagnosis kit. The present invention shows that the RP11‑22O19.2 inhibitor has a significant therapeutic effect on tumors. In addition, detecting the expression level of RP11-224O19.2 can be used for auxiliary diagnosis and prognosis judgment of clinical liver cancer, and has a good application prospect.